First clinical implementation of GammaTile permanent brain implants after FDA clearance

GammaTile cesium-131 (131Cs) permanent brain implant has received Food and Drug Administration (FDA) clearance as a promising treatment for certain brain tumors. Our center was the first institution in the United States after FDA clearance to offer the clinical use of GammaTile brachytherapy outside of a clinical trial. The purpose of this work is to aid the medical physicist and radiation oncologist in implementing this collagen carrier tile brachytherapy (CTBT) program in their practice.

Source: Brachytherapy - January 21, 2021 Category: Cancer & Oncology Authors: Clara Ferreira, David Sterling, Margaret Reynolds, Kathryn Dusenbery, Clark Chen, Parham Alaei Source Type: research